Literature DB >> 10172459

Tacrine for Alzheimer's disease. Costs and benefits.

D Knopman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 10172459     DOI： 10.2165/00019053-199507040-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  31 in total

1.  Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.

Authors:  G Chatellier; L Lacomblez
Journal:  BMJ       Date:  1990-02-24

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Effects of oral physostigmine in Alzheimer's disease.

Authors:  Y Stern; M Sano; R Mayeux
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

4.  Tacrine in Alzheimer's disease.

Authors:  S A Eagger; R Levy; B J Sahakian
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

5.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

6.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

Authors:  S T DeKosky; S W Scheff
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

7.  Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975.

Authors:  E Kokmen; C M Beard; K P Offord; L T Kurland
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

8.  Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study.

Authors:  D L Bachman; P A Wolf; R Linn; J E Knoefel; J Cobb; A Belanger; R B D'Agostino; L R White
Journal:  Neurology       Date:  1992-01       Impact factor: 9.910

9.  Lack of association between Alzheimer's disease and education, occupation, marital status, or living arrangement.

Authors:  C M Beard; E Kokmen; K P Offord; L T Kurland
Journal:  Neurology       Date:  1992-11       Impact factor: 9.910

Review 10.  Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.

Authors:  L J Thal; D M Masur; A D Blau; P A Fuld; M R Klauber
Journal:  J Am Geriatr Soc       Date:  1989-01       Impact factor: 5.562
View more
  3 in total

Review 1.  The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together.

Authors:  F J Molnar; W B Dalziel
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

2.  Evaluating the costs of alternative options for dementia services.

Authors:  T J Chaussalet; P H Millard; E el-Darzi
Journal:  Health Care Manag Sci       Date:  1998-10

Review 3.  Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.

Authors:  Anders Wimo
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.